Latest News

Co. Still Compelling After Drug Trial Failure

December 30, 2021 (Investorideas.com Newswire) “Arcalyst remains the value driver” for Kiniksa Pharmaceuticals, and “we continue to hold a favorable view of the company

You may also like

Leave a reply

Your email address will not be published.

More in Latest News